Disparity in the Markers of Affordability Across Targeted- and Immune-Therapy Drugs Used in Head and Neck Cancers.

Key Points

• The study aims to evaluate the pricing disparity of immunotherapy and targeted therapy drugs in head and neck cancers.
• Reviewed current pricing of immune and targeted therapy drugs for head and neck cancers.
• Analyzed survival benefits associated with these therapies.
• Identified barriers to accessibility based on pricing.
• Proposed policy reform strategies to improve affordability.
• Current immunotherapy prices significantly limit patient access globally.
• Modest survival benefits do not justify high costs of treatment.
• Policy reforms are necessary to ensure equitable access to cancer care.